Inactive Instrument

PERRIGO Share Price TEL AVIV STOCK EXCHANGE

Equities

Pharmaceuticals

End-of-day quote TEL AVIV STOCK EXCHANGE
- ILa - Intraday chart for PERRIGO

Financials

Sales 2024 * 4.62B 1,675B 355B Sales 2025 * 4.83B 1,751B 371B Capitalization 3.69B 1,339B 283B
Net income 2024 * -74M -26.83B -5.68B Net income 2025 * 103M 37.35B 7.91B EV / Sales 2024 * 1.49 x
Net Debt 2024 * 3.21B 1,163B 246B Net Debt 2025 * 3.01B 1,092B 231B EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
-18.7 x
P/E ratio 2025 *
169 x
Employees -
Yield 2024 *
4.07%
Yield 2025 *
4.33%
Free-Float 99.66%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 55 29/06/23
Director of Finance/CFO 49 15/05/22
Chief Tech/Sci/R&D Officer - 31/12/14
Members of the board TitleAgeSince
Chairman 55 14/12/20
Director/Board Member 68 05/02/17
Director/Board Member 67 05/02/17
More insiders
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
More about the company